KBH-A42
KBH-A42 is a novel histone deacetylase (HDAC) inhibitor with significant anti-inflammatory properties. KBH-A42 against TNF-α and NO production with IC50 values of 1.10 and 2.71 µM, respectively, in the LPS-induced murine macrophage RAW 264.7 cells.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 798543-50-7
- Formel: C17H22N2O3
- Molecular Weight:302.37
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| ACHN | GI50 |
1.17 μM
Compound: 14c
|
Growth inhibition of ACHN cells by SRB assay
Growth inhibition of ACHN cells by SRB assay
|
[PMID: 17477518] |
| ACHN | GI50 |
1.17 μM
Compound: 4h
|
Cytotoxicity against human ACHN cells
Cytotoxicity against human ACHN cells
|
[PMID: 21256006] |
| HCT-15 | GI50 |
4.99 μM
Compound: 14c
|
Growth inhibition of HCT15 cells by SRB assay
Growth inhibition of HCT15 cells by SRB assay
|
[PMID: 17477518] |
| HCT-15 | GI50 |
4.99 μM
Compound: 4h
|
Cytotoxicity against human HCT15 cells
Cytotoxicity against human HCT15 cells
|
[PMID: 21256006] |
| HeLa | IC50 |
0.27 μM
Compound: 14c
|
Inhibition of HDAC in HeLa cells by fluorescent activity assay
Inhibition of HDAC in HeLa cells by fluorescent activity assay
|
[PMID: 17477518] |
| LOX IMVI | GI50 |
3.34 μM
Compound: 14c
|
Growth inhibition of LOX-IMVI cells by SRB assay
Growth inhibition of LOX-IMVI cells by SRB assay
|
[PMID: 17477518] |
| LOX IMVI | GI50 |
3.34 μM
Compound: 4h
|
Cytotoxicity against human LOXIMVI cells
Cytotoxicity against human LOXIMVI cells
|
[PMID: 21256006] |
| MDA-MB-231 | GI50 |
0.5 μM
Compound: 14c
|
Growth inhibition of human MDA-MB-231 cells by SRB assay
Growth inhibition of human MDA-MB-231 cells by SRB assay
|
[PMID: 17477518] |
| MDA-MB-231 | GI50 |
0.5 μM
Compound: 4h
|
Cytotoxicity against human MDA-MB-231 cells
Cytotoxicity against human MDA-MB-231 cells
|
[PMID: 21256006] |
| NCI-H23 | GI50 |
3.79 μM
Compound: 14c
|
Growth inhibition of NCI-H23 cells by SRB assay
Growth inhibition of NCI-H23 cells by SRB assay
|
[PMID: 17477518] |
| NCI-H23 | GI50 |
3.79 μM
Compound: 4h
|
Cytotoxicity against human NCI-H23 cells
Cytotoxicity against human NCI-H23 cells
|
[PMID: 21256006] |
| PC-3 | GI50 |
5.04 μM
Compound: 14c
|
Growth inhibition of PC3 cells by SRB assay
Growth inhibition of PC3 cells by SRB assay
|
[PMID: 17477518] |
| PC-3 | GI50 |
6.98 μM
Compound: 4h
|
Cytotoxicity against human PC3 cells
Cytotoxicity against human PC3 cells
|
[PMID: 21256006] |
| RAW264.7 | IC50 |
1.1 μM
Compound: 14c
|
Inhibition of LPS-stimulated TNFalpha production in RAW264.7 cells after 24 hrs by ELISA
Inhibition of LPS-stimulated TNFalpha production in RAW264.7 cells after 24 hrs by ELISA
|
[PMID: 17477518] |
| RAW264.7 | IC50 |
2.71 μM
Compound: 14c
|
Inhibition of LPS-stimulated NO production in RAW264.7 cells after 24 hrs by ELISA
Inhibition of LPS-stimulated NO production in RAW264.7 cells after 24 hrs by ELISA
|
[PMID: 17477518] |
Chemical Information
-
CAS. Nr. 798543-50-7
-
Molecular Weight 302.37
-
Formel C17H22N2O3
-
SMILES
O=C(CCC1=CCCN(C1=O)CCCC2=CC=CC=C2)NO
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Phagocytosis Functional Assay
A phagocytosis functional assay measures the ability of phagocytic cells, such as neutrophils, macrophages, monocytes, or microglia/macrophages, to bind and internalize particulate targets including bacteria, yeast particles, beads, or myelin particles. Fluorescent flow-cytometry assays detect target uptake as fluorescence associated with gated phagocytes, while pH-sensitive dyes such as pHrodo increase signal in acidic phagosomal compartments and therefore preferentially report internalized particles rather than particles remaining outside the cell. Microscopy or high-content imaging can be used to confirm intracellular localization and, in some protocols, to follow uptake kinetics.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)